Caris Life Sciences (CAI) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
5 Jun, 2026Opening remarks and agenda
Meeting opened by CEO, with participation from CFO, General Counsel, and independent auditors present for Q&A.
Shareholders were welcomed and informed about the agenda and voting procedures.
Board and executive committee updates
Ten nominees were presented for election to the board for terms expiring at the 2027 annual meeting.
Shareholder proposals
Two proposals were presented: election of directors and ratification of the independent auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Caris Life Sciences
- Rapid growth in precision oncology, AI-driven innovation, and strong financial performance.CAI
Goldman Sachs 47th Annual Global Healthcare Conference 20268 Jun 2026 - Q1 2026 revenue up 79% to $216.2M, gross margin 65%, net loss narrowed, strong outlook.CAIQ1 202614 May 2026
- Rapid growth and innovation in precision oncology, with robust financial and clinical momentum.CAIBank of America Global Healthcare Conference 202612 May 2026
- Virtual meeting to elect directors and ratify Deloitte as auditor, with strong governance focus.CAIProxy filing23 Apr 2026
- Election of ten directors and auditor ratification headline the June 2026 annual meeting.CAIProxy filing23 Apr 2026
- Record 2025 revenue and margin gains; 2026 outlook targets $1B+ revenue and continued growth.CAIQ4 202511 Apr 2026
- Record revenue growth, MCED launch, and major partnerships drive transformative expansion.CAI44th Annual J.P. Morgan Healthcare Conference12 Jan 2026
- IPO targets $364.6M to fund AI-powered oncology solutions; rapid growth, but ongoing losses.CAIRegistration Filing29 Nov 2025
- IPO targets $419M+ to fund AI-powered oncology solutions amid rapid growth and ongoing losses.CAIRegistration Filing29 Nov 2025